17:52 , Aug 10, 2017 |  BC Innovations  |  Emerging Company Profile

Flexing against suppression

FLX Bio Inc. is creating small molecules to dim immunosuppressive actors in the tumor microenvironment without the baggage of the antibodies dominating the immuno-oncology space. Armed with $79 million in series A and B funds,...
19:25 , Jul 31, 2017 |  BC Innovations  |  Distillery Techniques

Chemistry

TECHNOLOGY: Tool compounds A quinolin-2-one-based inhibitor of BRPF1 , BRPF3 and BRD1 could be useful for probing the roles of the proteins in cancer and inflammation. Chemical synthesis and...
07:00 , Oct 20, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Patient sample and mouse studies suggest cutaneous expression of the Treg-attracting chemokine CCL22 could help treat metastatic melanoma. In samples of patient skin metastases, levels of CCL22 were higher than in healthy volunteer...
07:00 , Sep 26, 2016 |  BC Week In Review  |  Company News

Max Delbrueck Center for Molecular Medicine Berlin-Buch, Wilex deal

The Max Delbrueck Center ( MDC ) granted Wilex’s Heidelberg Pharma GmbH subsidiary an option to license humanized antibodies against tumor necrosis factor (TNF) receptor superfamily member 17 ( BCMA ; TNFRSF17 ; CD269 )....
07:00 , May 28, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Phosphodiesterase 3A, bGMP-inhibited (PDE3A)

Cardiovascular disease INDICATION: Hypertension Genetic and in vitro studies suggest inhibiting PDE3A on vascular smooth muscle cells could help treat inherited hypertension and brachydactyly type E (HTNB). Whole-genome sequencing of 48 HTNB patients from 6...
07:00 , Mar 24, 2014 |  BC Week In Review  |  Clinical News

BNC105: Phase II data

Data from 136 evaluable patients with metastatic RCC who failed prior tyrosine kinase inhibitor (TKI) therapy in the Phase II portion of the open-label, dose-escalation, international Phase I/II DISRUPTOR-1 trial showed that IV BNC105 plus...
08:00 , Nov 21, 2013 |  BC Innovations  |  Targets & Mechanisms

Getting to the root of periodontitis

Current periodontitis therapies do not target the underlying immune response that drives the disease. A team from the U.S. and Brazil is looking to change that and has shown that microparticles loaded with chemokine CC...
08:00 , Nov 21, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Dental disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Dental disease Periodontitis Chemokine CC motif ligand 22 (CCL22) Animal studies suggest CCL22-loaded microparticles could help treat periodontitis. In mouse models of...
07:00 , May 2, 2011 |  BC Week In Review  |  Company News

Affitech, Cancer Research U.K. deal

Affitech received exclusive, worldwide rights from Cancer Research's Cancer Research Technology Ltd. commercial arm to a patent application and IP to develop antibodies against tumor protein CC chemokine receptor 4 (CCR4; CD194 ). Affitech said...
07:00 , Oct 29, 2009 |  BC Innovations  |  Targets & Mechanisms

Wnt it rains

For the second time in as many months, a research group has found a new target in the Wnt pathway that could be more druggable than previously identified components of the cancer-inducing signaling cascade. Antagonizing...